FDA Grants NeoVista's Request To Expand CABERNET Trial To 30 Sites In The U.S. (Medical News Today)
NeoVista, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted the company's request to expand the number of sites participating in its pivotal Phase 3 trial from 10 to 30 in the United States.

IMPAX Reports FDA Finding That Budeprion XL(R) 300 mg Is Safe and Effective (Centre Daily Times)
IMPAX Laboratories, Inc. (OTC: IPXL) reports that the U.S. Food and Drug Administration (FDA) has issued its report concerning the Therapeutic Equivalence of Generic Bupropion XL 300 mg and Wellbutrin XL 300 mg and found that our generic buproprion extended-release tablets, marketed as Budeprion XL 300 milligram by our partner Teva Pharmaceutical USA, is a safe and effective choice for consumers ...